Eisen, Alon <br/><br/>
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.  [electronic resource] 

 -  American heart journal  Feb 2016 
 - 144-51 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1097-6744 
<br/><br/><label>Standard No.: </label>10.1016/j.ahj.2015.11.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Anticoagulants--administration & dosage<br/>Atrial Fibrillation--complications<br/>Blood Coagulation--drug effects<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Approval<br/>Factor Xa--drug effects<br/>Factor Xa Inhibitors--administration & dosage<br/>Female<br/>Humans<br/>Male<br/>Myocardial Infarction--complications<br/>Pyridines--administration & dosage<br/>Stroke--blood<br/>Thiazoles--administration & dosage<br/>Thrombolytic Therapy--methods<br/>United States<br/>United States Food and Drug Administration<br/>Warfarin--administration & dosage